Title:
【発明の名称】神経ペプチドY5レセプターアンタゴニスト
Document Type and Number:
Japanese Patent JP2002517483
Kind Code:
A
Abstract:
Compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein a and b are 0-2, provided that the sum is 0-3; Q is (i) or (-N=); X is -O-, -S-, -SO-, -SO2-, -CH(OR<8>)-, -C(O)-, -C(R<23>)2-, optionally substituted alkenyl, alkynyl or (ii); R<1> is optionally substituted aryl, heteroaryl, substituted amino, alkyl-OC(O)R<8>, aryloxyalkyl, (iii) wherein m is 1-4, or (iv) wherein d and e are 0-2; R<2>, R<3>, R<4> and R<5> are H, alkyl, optionally substituted cycloalkyl, halogen, -OR<8>, -N(R<8>)2, -CO2R<8> or CF3; R<6> and R<7> are H, alkyl, alkenyl, hydroxyalkyl, aminoalkyl, alkoxyalkyl, cycloalkyl or cycloalkylalkyl, or R<6> and R<7>, form a 3-7-membered carbocyclic ring, or a 4-7-membered heterocyclic ring; R<8> is H, alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R<9> is alkyl, cycloalkyl, optionally substituted aryl or heteroaryl; R<11> is H, alkyl or cycloalkyl; and R<23> is R<8> or halogen; are claimed, as well as additional novel compounds; also claimed are pharmaceutical compositions and methods of using said novel compounds in the treatment of eating disorders and diabetes.
Inventors:
Dagger, sandeep
New Stud, Bernard Earl.
Stanford, Andrew W.
U, Yushen
New Stud, Bernard Earl.
Stanford, Andrew W.
U, Yushen
Application Number:
JP2000553404A
Publication Date:
June 18, 2002
Filing Date:
June 07, 1999
Export Citation:
Assignee:
Schering Corporation
International Classes:
A61K31/10; A61K31/167; A61K31/17; A61K31/18; A61K31/4164; A61K31/438; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4418; A61K31/445; A61K31/4468; A61K31/451; A61K31/47; A61K31/472; A61K31/495; A61K31/496; A61K31/5375; A61K31/54; A61K31/55; A61P3/04; A61P3/10; C07C233/25; C07C233/29; C07C275/30; C07C275/32; C07C275/34; C07C275/38; C07C311/05; C07C323/29; C07C323/32; C07C323/39; C07C323/41; C07C323/44; C07D211/26; C07D211/58; C07D211/60; C07D211/96; C07D213/40; C07D213/74; C07D213/75; C07D215/08; C07D295/12; C07D217/06; C07D223/04; C07D223/22; C07D233/64; C07D295/14; C07D295/20; C07D295/215; C07D491/113; C07D498/10; (IPC1-7): C07C233/25; A61K31/10; A61K31/167; A61K31/17; A61K31/18; A61K31/4164; A61K31/438; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/445; A61K31/4468; A61K31/47; A61K31/472; A61K31/495; A61K31/496; A61K31/5375; A61K31/54; A61K31/55; A61P3/04; A61P3/10; C07C233/29; C07C275/34; C07C311/05; C07C323/29; C07C323/32; C07C323/39; C07D211/26; C07D211/58; C07D211/60; C07D211/96; C07D213/40; C07D213/74; C07D213/75; C07D217/06; C07D223/04; C07D223/22; C07D233/64; C07D295/12; C07D295/14; C07D295/20; C07D491/113
Attorney, Agent or Firm:
Shusaku Yamamoto